Status:
COMPLETED
Sitagliptin Umbilical Cord Blood Transplant Study
Lead Sponsor:
Indiana University School of Medicine
Conditions:
Leukemia, Myeloid, Acute
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
18-59 years
Phase:
PHASE2
Brief Summary
The main purpose of this trial is to study whether the drug sitagliptin can be given safely to patients undergoing umbilical cord blood transplantation to speed up engraftment (recovery of blood count...
Detailed Description
Umbilical cord blood (UCB) is increasingly used as a source of stem cells for patients with blood cancers who need an allogeneic stem cell transplant (a transplant with stem cells from another person)...
Eligibility Criteria
Inclusion
- Patients must have one of the following disease types with disease-specific features as outlined in the protocol:
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Myelodysplasia
- Chronic myelogenous leukemia
- Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma
- Hodgkin's lymphoma
- Relapsed Multiple Myeloma
- At least 35 days following start of preceding leukemia induction cytotoxic chemotherapy
- Patient age 18-55 years
- Karnofsky Performance status ≥ 70%
- No availability of a consenting HLA-matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB1.
- No availability of a readily available HLA-matched volunteer unrelated donor (8 of 8 allele match at HLA-A, -B, -C and -DRB1). Patients with unstable disease who are in danger of significant disease progression while waiting to procure volunteer donor cells will be eligible to be treated on this protocol, even if a matched donor is available.
- Patients must have a matched or partially matched UCB unit with greater than 1.8 x10-7 nucleated cells/kg of recipient weight at the time of cryopreservation.
- No current uncontrolled bacterial, viral or fungal infection (defined as currently taking medication and progression of clinical symptoms).
- No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.
- Non pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks.
- Required baseline laboratory values as defined in the protocol
Exclusion
- Symptomatic uncontrolled coronary artery disease or congestive heart failure.
- Severe hypoxemia with room air PaO2 less than 70, supplemental oxygen dependence, or DLCO less than 50 percent predicted
- Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy
- Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00862719
Start Date
March 1 2009
End Date
February 1 2015
Last Update
October 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IU Simon Cancer Center
Indianapolis, Indiana, United States, 46202